CoChat
Sign Up
Cited by 143Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesChronic Obstructive Pulmonary Disease (COPD) Research

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study

Gonzales, David H., Nides, Mitchell A., Ferry, Linda H., Kustra, Robert P., Jamerson, Brenda D., Segall, Nathan, Herrero, Luis A., Krishen, Alok +3 more·2001·Clinical Pharmacology & Therapeutics
DOI 10.1067/mcp.2001.115750
Open this paper in CoChat — free account

Abstract

BACKGROUND: Many persons who attempt to quit smoking have made previous unsuccessful attempts to quit with pharmacologic aids. An understanding of the impact of these previous attempts to quit is vital for selecting medications that may be more successful in a future attempt to quit. In particular, the effect of repeated use of bupropion SR (Zyban; INN, amfebutamone) on abstinence rates has not been studied previously. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled study in 450 smokers who had previously used bupropion in a smoking cessation attempt. The study consisted of a screening phase, a 12-week treatment phase, and a follow-up at month 6. Participants made regular clinic visits throughout the treatment phase during which they received brief counseling sessions to encourage abstinence from smoking. The primary end point was continuous abstinence from smoking from weeks 4 through 7. Secondary efficacy end points were examined throughout the treatment phase and at follow-up after 6 months. RESULTS: In participants receiving bupropion SR, 27% (61 of 226) remained abstinent throughout the period from weeks 4 through 7 compared with 5% (11 of 224) of participants receiving placebo (P <.001). Significantly (P <.001) more participants who received bupropion SR during the treatment phase remained continuously abstinent from the start of week 4 through month 6 (27 of 226; 12%) compared with participants who received placebo (5 of 224; 2%). Eleven participants receiving placebo (5%) and 19 participants receiving bupropion SR (8%) stopped taking the study medication because of an adverse event. CONCLUSIONS: Bupropion SR is an effective medication for retreatment of smokers who have used bupropion SR previously.

Integrity signals

Registry

Crossref · 10.1067/mcp.2001.115750

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Repeated use of bupropion in smokers who had previously failed to quit with bupropion led to significantly greater continuous abstinence rates compared to placebo (12% vs 2%).

    “On the other hand, repeated use of bupropion in smokers who had previously failed to quit with bupropion led to significantly greater continuous abstinence rates compared to placebo (12% vs. 2%; 122).”

    From Tobacco addiction (2008) · cites this paper as [122]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Gonzales, D. H., Nides, M. A., Ferry, L. H., Kustra, R. P., Jamerson, B. D., Segall, N., Herrero, L. A., Krishen, A., Sweeney, A., Buaron, K., & Metz, A.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Gonzales, David H.
ORCID
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2001-06
Volume
69
Issue
6
Pages
438-444
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
DOI
10.1067/mcp.2001.115750
OpenAlex
W2133374870
Cited by
143
References
11
Citations by year
2026: 1 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 2 · 2019: 1 · 2017: 1 · 2016: 4 · 2014: 3 · 2013: 6 · 2012: 7
FWCI
8.97
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 18 d)
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
bupropion, smoking cessation, retreatment, nicotine dependence, smoking abstinence, adverse events
MeSH terms
Adult, Double-Blind Method, Female, Humans, Male, Smoking Cessation, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review